What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the ZUMA-3 trial indicates that brexucabtagene autoleucel may improve overall survival and delay disease relapse compared to standard treatments. However, the lack of a direct comparator and uncertainties regarding the curative potential limit the strength of the evidence. The committee noted that while there are positive signals, the overall effectiveness remains uncertain.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for brexucabtagene autoleucel are uncertain, with some scenarios exceeding NICE’s acceptable thresholds. The committee concluded that while there is potential for cost-effectiveness, the current evidence does not support routine use due to high ICERs in many scenarios.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that patients receiving brexucabtagene autoleucel do not achieve the same quality of life as the general population, primarily due to cumulative toxicity from previous treatments and the disease itself. While CAR T-cell therapy is better tolerated than some alternatives, the overall impact on HRQoL is still negative, leading to a B+ rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Brexucabtagene autoleucel has a favorable safety profile compared to traditional treatments like allo-SCT, with manageable short-term side effects. The committee noted that while there are risks, they are generally less severe than those associated with existing therapies, justifying a strong rating.
Was the drug compared against what payers expect? — Comparator Selection
The company compared brexucabtagene autoleucel with appropriate comparators such as inotuzumab and blinatumomab. However, the absence of a direct head-to-head comparison limits the robustness of the evidence, leading to a B++ rating.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included a diverse group of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia, and the committee noted that the treatment is expected to be effective across different subgroups. This broad representation supports a solid rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Brexucabtagene autoleucel can be integrated into existing treatment pathways with minor adjustments, as it is a CAR T-cell therapy that fits within the current oncology framework. The committee noted that while some changes are necessary, they are manageable.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of brexucabtagene autoleucel are significant, with high costs associated with its delivery. While the potential for cost-effectiveness exists, the overall budget impact raises concerns, leading to a B+ rating.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base primarily relies on a single-arm trial (ZUMA-3), which introduces uncertainty and potential bias. While the trial was well-conducted, the lack of comparative data limits the robustness of the findings, justifying a B++ rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effectiveness and cost-effectiveness of brexucabtagene autoleucel. The committee noted that while there are potential benefits, the uncertainties surrounding the evidence and its implications for broader health equity issues lead to a B+ rating.
